COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).
Identifieur interne : 001210 ( Main/Corpus ); précédent : 001209; suivant : 001211COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).
Auteurs : Yang Song ; Min Zhang ; Ling Yin ; Kunkun Wang ; Yiyi Zhou ; Mi Zhou ; Yun LuSource :
- International journal of antimicrobial agents [ 1872-7913 ] ; 2020.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Humans, Pandemics, SARS-CoV-2.
Abstract
Currently, there is no approved therapy for coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) therefore endorses supportive care only. However, frontline clinicians and researchers have been experimenting with several virus-based and host-based therapeutics since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China. China's National Health Commission has issued the first COVID-19 treatment guidelines with therapy suggestions, which has inspired clinical studies worldwide. This review evaluates the major therapeutics. Key evidence from in vitro research, animal models and clinical research in emerging coronaviruses is examined. The antiviral therapies remdesivir, lopinavir/ritonavir and umifenovir, if considered, should be initiated before the peak of viral replication for an optimal outcome. Ribavirin may be beneficial as an add-on therapy but is ineffective as monotherapy. Corticosteroid use should be limited to specific co-morbidities. Intravenous immunoglobulin (IVIg) is not recommended owing to lack of data in COVID-19. The traditional Chinese medicine Xuebijing may benefit patients with complications of bacterial pneumonia or sepsis. The efficacy of interferon is unclear owing to conflicting outcomes in coronavirus studies. Chloroquine and hydroxychloroquine have shown in vitro inhibition of SARS-CoV-2, but studies on their clinical efficacy and whether the benefits outweigh the risk of dysrhythmias remain inconclusive. For patients who develop cytokine release syndrome, interleukin-6 inhibitors may be beneficial.
DOI: 10.1016/j.ijantimicag.2020.106080
PubMed: 32634603
PubMed Central: PMC7334905
Links to Exploration step
pubmed:32634603Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).</title><author><name sortKey="Song, Yang" sort="Song, Yang" uniqKey="Song Y" first="Yang" last="Song">Yang Song</name><affiliation><nlm:affiliation>Department of Pharmacy Services, CHI Franciscan Health-St Joseph Medical Center, Tacoma, WA 98405, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Min" sort="Zhang, Min" uniqKey="Zhang M" first="Min" last="Zhang">Min Zhang</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Boston Medical Center, Boston, MA 02118, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yin, Ling" sort="Yin, Ling" uniqKey="Yin L" first="Ling" last="Yin">Ling Yin</name><affiliation><nlm:affiliation>Department of Pharmacy Services, AdventHealth Celebration Cancer Institute, Celebration, FL 34747, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Kunkun" sort="Wang, Kunkun" uniqKey="Wang K" first="Kunkun" last="Wang">Kunkun Wang</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Fairbanks Memorial Hospital, Fairbanks, AK 99701, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Yiyi" sort="Zhou, Yiyi" uniqKey="Zhou Y" first="Yiyi" last="Zhou">Yiyi Zhou</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Beijing United Family Hospital, Beijing 100016, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Mi" sort="Zhou, Mi" uniqKey="Zhou M" first="Mi" last="Zhou">Mi Zhou</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Children's Hospital of Soochow University, Suzhou 215000, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lu, Yun" sort="Lu, Yun" uniqKey="Lu Y" first="Yun" last="Lu">Yun Lu</name><affiliation><nlm:affiliation>Associate Clinical Professor, University of Minnesota, and Department of Pharmacy Services, Hennepin County Medical Center, Minneapolis, MN 55415, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32634603</idno><idno type="pmid">32634603</idno><idno type="doi">10.1016/j.ijantimicag.2020.106080</idno><idno type="pmc">PMC7334905</idno><idno type="wicri:Area/Main/Corpus">001210</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001210</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).</title><author><name sortKey="Song, Yang" sort="Song, Yang" uniqKey="Song Y" first="Yang" last="Song">Yang Song</name><affiliation><nlm:affiliation>Department of Pharmacy Services, CHI Franciscan Health-St Joseph Medical Center, Tacoma, WA 98405, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zhang, Min" sort="Zhang, Min" uniqKey="Zhang M" first="Min" last="Zhang">Min Zhang</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Boston Medical Center, Boston, MA 02118, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Yin, Ling" sort="Yin, Ling" uniqKey="Yin L" first="Ling" last="Yin">Ling Yin</name><affiliation><nlm:affiliation>Department of Pharmacy Services, AdventHealth Celebration Cancer Institute, Celebration, FL 34747, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Kunkun" sort="Wang, Kunkun" uniqKey="Wang K" first="Kunkun" last="Wang">Kunkun Wang</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Fairbanks Memorial Hospital, Fairbanks, AK 99701, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Yiyi" sort="Zhou, Yiyi" uniqKey="Zhou Y" first="Yiyi" last="Zhou">Yiyi Zhou</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Beijing United Family Hospital, Beijing 100016, China.</nlm:affiliation></affiliation></author><author><name sortKey="Zhou, Mi" sort="Zhou, Mi" uniqKey="Zhou M" first="Mi" last="Zhou">Mi Zhou</name><affiliation><nlm:affiliation>Department of Pharmacy Services, Children's Hospital of Soochow University, Suzhou 215000, China.</nlm:affiliation></affiliation></author><author><name sortKey="Lu, Yun" sort="Lu, Yun" uniqKey="Lu Y" first="Yun" last="Lu">Yun Lu</name><affiliation><nlm:affiliation>Associate Clinical Professor, University of Minnesota, and Department of Pharmacy Services, Hennepin County Medical Center, Minneapolis, MN 55415, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">International journal of antimicrobial agents</title><idno type="eISSN">1872-7913</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (isolation & purification)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (virology)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (virology)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>COVID-19</term><term>Humans</term><term>Pandemics</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Currently, there is no approved therapy for coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) therefore endorses supportive care only. However, frontline clinicians and researchers have been experimenting with several virus-based and host-based therapeutics since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China. China's National Health Commission has issued the first COVID-19 treatment guidelines with therapy suggestions, which has inspired clinical studies worldwide. This review evaluates the major therapeutics. Key evidence from in vitro research, animal models and clinical research in emerging coronaviruses is examined. The antiviral therapies remdesivir, lopinavir/ritonavir and umifenovir, if considered, should be initiated before the peak of viral replication for an optimal outcome. Ribavirin may be beneficial as an add-on therapy but is ineffective as monotherapy. Corticosteroid use should be limited to specific co-morbidities. Intravenous immunoglobulin (IVIg) is not recommended owing to lack of data in COVID-19. The traditional Chinese medicine Xuebijing may benefit patients with complications of bacterial pneumonia or sepsis. The efficacy of interferon is unclear owing to conflicting outcomes in coronavirus studies. Chloroquine and hydroxychloroquine have shown in vitro inhibition of SARS-CoV-2, but studies on their clinical efficacy and whether the benefits outweigh the risk of dysrhythmias remain inconclusive. For patients who develop cytokine release syndrome, interleukin-6 inhibitors may be beneficial.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32634603</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International journal of antimicrobial agents</Title><ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation></Journal><ArticleTitle>COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).</ArticleTitle><Pagination><MedlinePgn>106080</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-8579(20)30250-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2020.106080</ELocationID><Abstract><AbstractText>Currently, there is no approved therapy for coronavirus disease 2019 (COVID-19). The World Health Organization (WHO) therefore endorses supportive care only. However, frontline clinicians and researchers have been experimenting with several virus-based and host-based therapeutics since the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China. China's National Health Commission has issued the first COVID-19 treatment guidelines with therapy suggestions, which has inspired clinical studies worldwide. This review evaluates the major therapeutics. Key evidence from in vitro research, animal models and clinical research in emerging coronaviruses is examined. The antiviral therapies remdesivir, lopinavir/ritonavir and umifenovir, if considered, should be initiated before the peak of viral replication for an optimal outcome. Ribavirin may be beneficial as an add-on therapy but is ineffective as monotherapy. Corticosteroid use should be limited to specific co-morbidities. Intravenous immunoglobulin (IVIg) is not recommended owing to lack of data in COVID-19. The traditional Chinese medicine Xuebijing may benefit patients with complications of bacterial pneumonia or sepsis. The efficacy of interferon is unclear owing to conflicting outcomes in coronavirus studies. Chloroquine and hydroxychloroquine have shown in vitro inhibition of SARS-CoV-2, but studies on their clinical efficacy and whether the benefits outweigh the risk of dysrhythmias remain inconclusive. For patients who develop cytokine release syndrome, interleukin-6 inhibitors may be beneficial.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, CHI Franciscan Health-St Joseph Medical Center, Tacoma, WA 98405, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Min</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, Boston Medical Center, Boston, MA 02118, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, AdventHealth Celebration Cancer Institute, Celebration, FL 34747, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Kunkun</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, Fairbanks Memorial Hospital, Fairbanks, AK 99701, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Yiyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, Beijing United Family Hospital, Beijing 100016, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Mi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacy Services, Children's Hospital of Soochow University, Suzhou 215000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Associate Clinical Professor, University of Minnesota, and Department of Pharmacy Services, Hennepin County Medical Center, Minneapolis, MN 55415, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Antimicrob Agents</MedlineTA><NlmUniqueID>9111860</NlmUniqueID><ISSNLinking>0924-8579</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">China's COVID-19 Guide</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">IL-6 inhibitor</Keyword><Keyword MajorTopicYN="N">Remdesivir</Keyword><Keyword MajorTopicYN="N">Xuebijing</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>06</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32634603</ArticleId><ArticleId IdType="pii">S0924-8579(20)30250-8</ArticleId><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106080</ArticleId><ArticleId IdType="pmc">PMC7334905</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Thorax. 2004 May;59(5):414-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15115870</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Jul;81(1):e1-e5</Citation><ArticleIdList><ArticleId IdType="pubmed">32171872</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2017 Jan;137:125-130</Citation><ArticleIdList><ArticleId IdType="pubmed">27890674</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):183-184</Citation><ArticleIdList><ArticleId IdType="pubmed">32164084</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2015 Jul;70(7):2129-32</Citation><ArticleIdList><ArticleId IdType="pubmed">25900158</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 15;395(10223):507-513</Citation><ArticleIdList><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation><ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Dec 24;290(24):3222-8</Citation><ArticleIdList><ArticleId IdType="pubmed">14693875</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation><ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 May 14;369:m1849</Citation><ArticleIdList><ArticleId IdType="pubmed">32409561</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation><ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation><ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2020 Jul;179:104811</Citation><ArticleIdList><ArticleId IdType="pubmed">32360182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 30;395(10238):1695-1704</Citation><ArticleIdList><ArticleId IdType="pubmed">32401715</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation><ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Med. 2019 Sep;47(9):e735-e743</Citation><ArticleIdList><ArticleId IdType="pubmed">31162191</ArticleId></ArticleIdList></Reference><Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):64-68</Citation><ArticleIdList><ArticleId IdType="pubmed">32037389</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Mar 17;323(11):1061-1069</Citation><ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Emerg Med. 2017 Feb;35(2):285-291</Citation><ArticleIdList><ArticleId IdType="pubmed">27852528</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 Feb 29;395(10225):683-684</Citation><ArticleIdList><ArticleId IdType="pubmed">32122468</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Transl Med. 2017 Jun 28;9(396):</Citation><ArticleIdList><ArticleId IdType="pubmed">28659436</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2006 Sep;3(9):e343</Citation><ArticleIdList><ArticleId IdType="pubmed">16968120</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Exp Immunol. 2005 Oct;142(1):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16178850</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Opin Biol Ther. 2004 Jun;4(6):827-36</Citation><ArticleIdList><ArticleId IdType="pubmed">15174965</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhonghua Yi Xue Za Zhi. 2012 Apr 17;92(15):1017-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22781640</ArticleId></ArticleIdList></Reference><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 May;92(5):491-494</Citation><ArticleIdList><ArticleId IdType="pubmed">32056249</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhongguo Wei Zhong Bing Ji Jiu Yi Xue. 2009 Jul;21(7):405-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19615131</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2020 Jul;92(7):791-796</Citation><ArticleIdList><ArticleId IdType="pubmed">32181911</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1827-1837</Citation><ArticleIdList><ArticleId IdType="pubmed">32459919</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Care Explor. 2020 Apr 29;2(4):e0111</Citation><ArticleIdList><ArticleId IdType="pubmed">32426753</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2004 May;10(5):818-24</Citation><ArticleIdList><ArticleId IdType="pubmed">15200814</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102</Citation><ArticleIdList><ArticleId IdType="pubmed">32258207</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation><ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2003 May 1;423(6935):4</Citation><ArticleIdList><ArticleId IdType="pubmed">12721587</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Infect Dis. 2014 Mar;20:42-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24406736</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 Mar;8(3):e11-e12</Citation><ArticleIdList><ArticleId IdType="pubmed">32061335</ArticleId></ArticleIdList></Reference><Reference><Citation>mBio. 2018 Mar 6;9(2):</Citation><ArticleIdList><ArticleId IdType="pubmed">29511076</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776</Citation><ArticleIdList><ArticleId IdType="pubmed">32054787</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Microbiol. 2003 Aug;52(Pt 8):715-720</Citation><ArticleIdList><ArticleId IdType="pubmed">12867568</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation><ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Transl Med. 2019 Sep;7(18):481</Citation><ArticleIdList><ArticleId IdType="pubmed">31700917</ArticleId></ArticleIdList></Reference><Reference><Citation>Med (N Y). 2020 Dec 18;1(1):114-127.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Apr 15;70(9):1837-1844</Citation><ArticleIdList><ArticleId IdType="pubmed">31925415</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Immunol. 2017 Dec 30;29(11):491-498</Citation><ArticleIdList><ArticleId IdType="pubmed">28666326</ArticleId></ArticleIdList></Reference><Reference><Citation>Med (N Y). 2020 Dec 18;1(1):105-113.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">32838353</ArticleId></ArticleIdList></Reference><Reference><Citation>Chembiochem. 2020 Mar 2;21(5):730-738</Citation><ArticleIdList><ArticleId IdType="pubmed">32022370</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2013 Dec;67(6):606-16</Citation><ArticleIdList><ArticleId IdType="pubmed">24096239</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 21;323(15):1488-1494</Citation><ArticleIdList><ArticleId IdType="pubmed">32125362</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation><ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2013;3:1686</Citation><ArticleIdList><ArticleId IdType="pubmed">23594967</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Aug;56(2):105974</Citation><ArticleIdList><ArticleId IdType="pubmed">32298745</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Intern Med. 2020 Jul 1;180(7):934-943</Citation><ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Ther Bull. 2010 May;48(5):57-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20447982</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Microbiol Infect. 2020 Jul;26(7):917-921</Citation><ArticleIdList><ArticleId IdType="pubmed">32344167</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767</Citation><ArticleIdList><ArticleId IdType="pubmed">29161116</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Sep;31(1):69-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15288617</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2020 Jun;26(6):808-809</Citation><ArticleIdList><ArticleId IdType="pubmed">32488217</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2014 Nov;14(11):1090-1095</Citation><ArticleIdList><ArticleId IdType="pubmed">25278221</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation><ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Rheum Dis Clin North Am. 2016 Feb;42(1):15-31, vii</Citation><ArticleIdList><ArticleId IdType="pubmed">26611548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001210 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001210 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32634603
|texte= COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32634603" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |